medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 3

<< Back Next >>

Med Int Mex 2022; 38 (3)

Treatment against high-risk smoldering multiple myeloma

Lugo-Bautista KS, Díaz-Greene EJ, Rodríguez-Weber FL

Language: Spanish
References: 25
Page: 560-570
PDF size: 206.13 Kb.


ABSTRACT

Objective: To review medical literature with the proposal of identifying promising new treatments against smoldering multiple myeloma.
Method: A search was made in PubMed of MeSH terms about smoldering multiple myeloma.
Results: A total of 196 results was obtained, and after their evaluation, 8 studies were included to carry out this review. Administration of lenalidomide, lenalidomidedexamethasone, or cafilzomib-lenalidomide-dexamethasone have been associated with increased disease-free survival time, or progression to a clonal phase.
Conclusions: To date, administration of lenalidomide or lenalidomide-dexamethasone is suggested as a promising treatment to stop the progression of smoldering multiple myeloma. However, there is no clinical practice guideline to suggest its use yet, so it is recommended that more high-quality clinical trials be conducted in the future with focus on its utility to treat this relatively novel disease.


REFERENCES

  1. Mateos MV, González-Calle V. Smoldering multiple myeloma:Who and when to treat. Clin Lymphoma Myeloma Leuk

  2. 2017; 17 (11): 716-722. doi: 10.1016/j.clml.2017.06.022.2. Hernández JÁ, Martínez-López J, Lahuerta JJ. Timingtreatment for smoldering myeloma: is earlier better?Expert Rev Hematol 2019; 12 (5): 345–54. https://doi.org/10.1080/17474086.2019.1599281.

  3. Kunacheewa C, Manasanch EE. High-risk smoldering myelomaversus early detection of multiple myeloma: Currentmodels, goals of therapy, and clinical implications. BestPract Res Clin Haematol 2020; 33 (1): 101152. https://doi.org/10.1016/j.beha.2020.101152

  4. Landgren O. Shall we treat smoldering multiple myelomain the near future? Hematology 2017; 1: 194-204. https://doi.org/10.1182/asheducation-2017.1.194

  5. Blum A, Bazou D, O’Gorman P. Smoldering multiple myeloma:prevalence and current evidence guiding treatmentdecisions. Blood Lymphat Cancer Targets Ther 2018; 8:21-31. doi: 10.2147/BLCTT.S136447.

  6. Rajkumar SV, Landgren O, Mateos MV. Smoldering multiplemyeloma. Blood 2015; 125 (20): 3069-75. doi: 10.1182/blood-2014-09-568899.

  7. Sundararajan S, Kumar A, Korde N, Agarwal A. Smolderingmultiple myeloma: Emerging concepts and therapeutics[Internet]. Vol. 11, Curr Hematol Malign Rep 2016; 11:102-10. doi: 10.1007/s11899-016-0305-6.

  8. Kyle RA, Durie BGM, Rajkumar S V., Landgren O, Blade J,Merlini G, et al. Monoclonal gammopathy of undeterminedsignificance (MGUS) and smoldering (asymptomatic)multiple myeloma: IMWG consensus perspectives riskfactors for progression and guidelines for monitoring andmanagement. Leukemia 2010; 24: 1121-7. doi: 10.1038/leu.2010.60.

  9. Caers J, Fernández de Larrea C, Leleu X, Heusschen R, ZojerN, Decaux O, et al. The changing landscape of smolderingmultiple myeloma: A European perspective. Oncologist2016; 21 (3): 333-42. doi: 10.1634/theoncologist.2015-0303.

  10. Muchtar E, Kumar SK, Magen H, Gertz MA. Diagnosis and managementof smoldering multiple myeloma: the razor’s edgebetween clonality and cancer. Leuk Lymphoma 2018; 59 (2):288-99. https://doi.org/10.1080/10428194.2017.1334124

  11. Wei Y, Lee RJ. Liposomal curcumin and its applicationin cancer. Int J Nanomedicine 2017; 12: 6027-44. doi:10.2147/IJN.S132434.

  12. Golombick T, Diamond TH, Manoharan A, Ramakrishna R.Monoclonal gammopathy of undetermined significance,smoldering multiple myeloma, and curcumin: A randomized,double-blind placebo-controlled cross-over 4g studyand an open-label 8g extension study. Am J Hematol 2012;87 (5): 455-60. https://doi.org/10.1002/ajh.23159.

  13. Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, OrlowskiRZ, et al. Randomized trial of lenalidomide versus observationin smoldering multiple myeloma. J Clin Oncol 2020; 38(11): 1126-1137. doi: 10.1200/JCO.19.01740.

  14. Chen N, Zhou S, Palmisano M. Clinical pharmacokineticsand pharmacodynamics of lenalidomide. Clin Pharmacokinet2017; 56 (2): 139-52. doi: 10.1007/s40262-016-0432-1.

  15. Korde N, Roschewski M, Zingone A, Kwok M, ManasanchEE, Bhutani M, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension inpatients with smoldering or newly diagnosed multiplemyeloma. JAMA Oncol 2015; 1 (6): 746-54. doi: 10.1001/jamaoncol.2015.2010.

  16. Strifler S, Knop S. The role of carfilzomib in treatment ofnewly diagnosed multiple myeloma. Futur Oncol 2018; 14(30): 3123-34. doi: 10.2217/fon-2018-0040.

  17. Ordóñez SG, Álvarez ÁM, Plata EL. Corticoides: 60 añosdespués, una asignatura pendiente. Rev Ciencias Salud2007; 5 (3): 58-69.

  18. Valencia AM, Manzano AR, Armendáriz KS, Sánchez PO,López PZ, Guerrero JA, et al. Thalidomide: From darknessto brightness. Dermatol CMQ 2011; 9 (4): 298-305.

  19. Ouyang Z, Li H, Zhai Z, Xu J, Dass CR, Qin A, et al. Zoledronicacid: pleiotropic anti-tumor mechanism and therapeuticoutlook for osteosarcoma. Curr Drug Targets 2018; 19 (5):409-21. doi: 10.2174/1573399811666150615145409.

  20. Witzig TE, Laumann KM, Lacy MQ, Hayman SR, DispenzieriA, Kumar S, et al. A phase III randomized trial of thalidomideplus zoledronic acid versus zoledronic acid alone in patientswith asymptomatic multiple myeloma. Leukemia 2013; 27(1): 220-5. doi: 10.1038/leu.2012.236.

  21. Passey C, Sheng J, Mora J, Tendolkar A, Robbins M, DodgeR, et al. The clinical pharmacology of elotuzumab. ClinPharmacokinet 2018; 57 (3): 297-313. doi: 10.1007/s40262-017-0585-6.

  22. Jagannath S, Laubach J, Wong E, Stockerl-Goldstein K, RosenbaumC, Dhodapkar M, et al. Elotuzumab monotherapyin patients with smouldering multiple myeloma: a phase 2study. Br J Haematol 2018; 182 (4): 495-503. doi: 10.1111/bjh.15384.

  23. Mateos MV, Hernández MT, Giraldo P, De La Rubia J, DeArriba F, Corral LL, et al. Lenalidomide plus dexamethasonefor high-risk smoldering multiple myeloma. N Engl J Med2013; 369 (5): 438-47. DOI: 10.1056/NEJMoa1300439.

  24. Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA,Witzig TE, et al. Induction of a chronic disease state inpatients with smoldering or indolent multiple myeloma bytargeting interleukin 1β-induced interleukin 6 productionand the myeloma proliferative component. Mayo Clin Proc2009; 84 (2): 114-22. doi: 10.4065/84.2.114.

  25. Wichert S, Juliusson G, Johansson Å, Sonesson E, TeigeI, Wickenberg AT, et al. A single-arm, open-label, phase2 clinical trial evaluating disease response followingtreatment with BI-505, a human anti-intercellular adhesionmolecule-1 monoclonal antibody, in patients with smolderingmultiple myeloma. PLoS One 2017; 12 (2): 1-12. doi:10.1371/journal.pone.0171205.




2020     |     www.medigraphic.com